Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 6/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.38 |
| ▸ | WNT3A | P56704 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17341974 | 0.91 | GABRA1 (0.47) | GABRA1GABRB2MTNR1AMTNR1BCTNNB1 | |
| SCHEMBL17345613 | 0.90 | GABRA1 (0.47) | GABRA1GABRB2MTNR1ACTNNB1WNT3A | |
| SCHEMBL17341969 | 0.82 | CTNNB1 (0.50) | GABRA1GABRB2MTNR1AMTNR1BCTNNB1 | |
| SCHEMBL17345611 | 0.81 | ADAM17 (0.49) | GABRA1GABRB2CTNNB1WNT3AGAA | |
| SCHEMBL17341979 | 0.79 | ALDH1A1 (0.38) | MAPTKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL17341960 | 0.75 | IAPP (0.35) | MTNR1AMTNR1BMAPTMEN1ALDH1A1 | |
| SCHEMBL17341970 | 0.74 | FAAH (0.37) | MTNR1AMTNR1BMAPTMEN1ALDH1A1 | |
| SCHEMBL25874897 | 0.72 | HTR2A (0.64) | MTNR1AMTNR1BGAAMAPTKDM4E | |
| SCHEMBL17341982 | 0.71 | CTNNB1 (0.50) | GABRA1GABRB2CTNNB1WNT3AGAA | |
| SCHEMBL16302212 | 0.70 | GAA (0.64) | MTNR1AMTNR1BGAAMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180029990-A1 | COMPOSITION AND METHOD FOR PREVENTION, MITIGATION OR TREATMENT OF AN ENTEROPATHOGENIC BACTERIAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-01 | — | — | US | disclosed |
| US-9790186-B2 | Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2017-10-17 | — | — | US | disclosed |
| US-20150361045-A1 | COMPOSITION AND METHOD FOR PREVENTION, MITIGATION OR TREATMENT OF AN ENTEROPATHOGENIC BACTERIAL INFECTION | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361045-A1 | COMPOSITION AND METHOD FOR PREVENTION, MITIGATION OR TREATMENT OF AN ENTEROPATHOGENIC BACTERIAL INFECTION | FABP2, LRBA, VIP | GABRA1 2168/4885GABRB2 956/4885MTNR1A 1249/4885 |
| US-20180029990-A1 | COMPOSITION AND METHOD FOR PREVENTION, MITIGATION OR TREATMENT OF AN ENTEROPATHOGENIC BACTERIAL INFECTION | FABP2, LRBA, VIP | GABRA1 2168/4885GABRB2 956/4885MTNR1A 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.